Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency.
about
Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europeEnhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenHizentra for the treatment of primary immunodeficiency.Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy.
P2860
Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Pharmacokinetic modeling and s ...... g in primary immunodeficiency.
@en
Pharmacokinetic modeling and s ...... g in primary immunodeficiency.
@nl
type
label
Pharmacokinetic modeling and s ...... g in primary immunodeficiency.
@en
Pharmacokinetic modeling and s ...... g in primary immunodeficiency.
@nl
prefLabel
Pharmacokinetic modeling and s ...... g in primary immunodeficiency.
@en
Pharmacokinetic modeling and s ...... g in primary immunodeficiency.
@nl
P2093
P2860
P356
P1476
Pharmacokinetic modeling and s ...... ng in primary immunodeficiency
@en
P2093
Jagdev Sidhu
Jianfeng Lu
Jonathan Edelman
Marc Pfister
Martin Bexon
Mikhail Rojavin
P2860
P356
10.3810/PGM.2013.11.2712
P407
P577
2013-11-01T00:00:00Z